Fatigue impacts up to 90% of patients with SLE [2]. The cause of fatigue is most likely multifactorial. Disease activity indices and laboratory markers inconsistently correlate with fatigue severity in SLE populations. An incomplete understanding of fatigue mechanisms limits effective treatment.
Therefore, the aim of the study by Christina Düsing (Universitätsklinikum Düsseldorf, Germany) was to identify additional potentially reversible associations with fatigue to generate a target for future interventions. Data came from 234 consecutively recruited SLE (according to the 1997 ACR criteria) outpatients from the university hospital-based lupus reference centre. Clinical and demographic data from routine visits, laboratory variables, as well as sleeping disorders, disease perception, coping, and social activities were analysed with validated questionnaires. The symptom fatigue was assessed using the Fatigue Severity Scale (FSS); 50% of the patients had pathological results (score of ≥4 points). The cohort was almost exclusively Caucasian (99.1%); 87.6% were female with a mean age of 45.3 years and a mean disease duration of 16.2 years.
Factors significantly associated with fatigue were depression (assessed by the German CES-D depression scale): 37.5% of patients with fatigue also showed depression versus 18.2% of patients without fatigue (P<0.001). In addition, patients with sleep disorders, pain, disease activity and damage showed significantly more fatigue (P<0.01). According to a regression analysis, reduced social activities exhibited the highest correlation with fatigue. Of note, in 71.4% of the cohort at least 1 potentially reversible association for fatigue could be identified (see Table). The authors concluded that due to the significant association with depression, psychological wellbeing of SLE patients should be assessed in everyday clinical practice. Additionally, optimising factors like obesity, anaemia, hypothyroidism, and vitamin D deficiency could represent possible targets in order to improve fatigue in SLE patients.
Table: Potentially reversible associations with fatigue in a cohort of 234 SLE patients, absolute numbers and percentages [1]
SLE, systemic lupus erythematosus; FSS, Fatigue Severity Scale; ADS-L, Allgemeine Depressions-Skala-Lang; TSH, thyroid-stimulating hormone
- Duesing Ch et al. Abstract 649. ACR 2019, 9-13 November, Atlanta (GA/USA).
- Mahieu MA, Ramsey-Goldman R. Curr Rheumatol Rev 2017;13; 103-12.
Posted on
Previous Article
« Cancer treatment with checkpoint inhibitors in RA patients? Next Article
Treatment decisions should not be guided by ultrasound findings »
« Cancer treatment with checkpoint inhibitors in RA patients? Next Article
Treatment decisions should not be guided by ultrasound findings »
Table of Contents: ACR 2019
Featured articles
Late-Breaking Abstracts
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
Calcium pyrophosphate deposition disease: an independent risk factor for cardiovascular complications
Proteome abnormalities improve prediction of RA development
RA patients in remission benefit from continued therapy with conventional DMARDs
Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis
Corticosteroid therapy in GCA: higher platelets – lower relapse rate
Spotlight on Rheumatoid Arthritis
Filgotinib promising in RA patients naïve to methotrexate
Sustained efficacy of monotherapy with upadacitinib after 48 weeks
Biologics show similar activity in patients with elderly-onset RA
Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration
Treatment decisions should not be guided by ultrasound findings
Cancer treatment with checkpoint inhibitors in RA patients?
What is Hot in Systemic Lupus Erythematosus
Anifrolumab succeeds in second phase 3 trial in SLE
Depression closely related to fatigue in SLE patients
Spondyloarthritis – The Beat Goes On
Psoriasis onset determines sequence of symptoms
Higher psychiatric comorbidity in women with PsA
JAK1 inhibition shows remarkable efficacy in AS
CARDAS study shows increased prevalence of cardiac valvular disorders in AS patients
Osteoarthritis – State-of-the-Art
Hand OA: low-dose corticosteroids improve symptoms
Opioids: no quality of life benefits for OA patients
Walking speed is a predictor of mortality in patients with knee OA
Reproductive Issues in Rheumatic Disease
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib
Prevention of congenital heart block may be possible with hydroxychloroquine
TNFi for RA during pregnancy – to stop or not to stop?
Vasculitis – Novel Treatment Modalities
Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis
Prolonged remission after stop of tocilizumab for patients with giant cell arteritis
Best of the Posters
Antifibrotic therapy slows disease progression independent of corticosteroid use
Fibromyalgia patients often experienced abuse in childhood
Related Articles
February 4, 2020
Sustained efficacy of monotherapy with upadacitinib after 48 weeks
February 4, 2020
Psoriasis onset determines sequence of symptoms
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com